nirmatrelvir/ritonavir

Nirmatrelvir

Absorption: Well absorbed.

Distribution: Extensively distributed to extravascular tissues.

Metabolism/Excretion: CYP3A4 substrate; minimal metabolism by this isoenzyme when coadministered with ritonavir. Excreted in feces (49.6%) and urine (35.3%);

Half-Life: 6 hr.

Ritonavir

Absorption: Well absorbed.

Distribution: Extensively distributed to extravascular tissues.

Protein Binding: 98–99%.

Metabolism/Excretion: Primarily metabolized in the liver via the CYP3A isoenzyme, and to a lesser extent by the CYP2D6 isoenzyme. Primarily excreted in feces (86.4%), with 11.3% excreted in urine.

Half-Life: 6 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
PO (nirmatrelvir)	unknown	3 hr	12 hr
PO (ritonavir)	unknown	4 hr	12 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Hypersensitivity;
Concurrent use of alfuzosin, amiodarone, apalutamide, carbamazepine, clozapine, colchicine, dihydroergotamine, dronedarone, ergotamine, flecainide, lovastatin, lurasidone, methylergonovine, midazolam (PO), phenobarbital, phenytoin, piroxicam, pimozide, propafenone, quinidine, ranolazine, rifampin, simvastatin, sildenafil (Revatio), St. John's wort, or triazolam;
Severe renal impairment (CCr <30 mL/min);
Severe hepatic impairment.

Use Cautiously in:

Moderate renal impairment (↓ dose);
OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk;
Lactation: Safety not established in breastfeeding;
Pedi: Safety and effectiveness not established in children.

Adv. Reactions/Side Effects ⬆ ⬇

CV: hypertension

Derm: STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS

GI: ↑liver enzymes, abdominal pain, diarrhea, nausea, vomiting

MS: myalgia

Neuro: dysgeusia, headache

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions ⬆ ⬇

Drug-drug:

May ↑ levels and risk of toxicity of some antiarrhythmics (amiodarone, dronedarone, flecainide, propafenone, quinidine), some antipsychotics (clozapine, pimozide, lurasidone), alfuzosin, ergot derivatives (dihydroergotamine, ergotamine, methylergonovine), colchicine, piroxicam, ranolazine, sildenafil (Revatio), midazolam (oral), and triazolam; concurrent use contraindicated.
May ↑ levels and risk of toxicity of lovastatin and simvastatin; concurrent use contraindicated; discontinue lovastatin and simvastatin ≥12 hr before starting nirmatrelvir/ritonavir
Apalutamide, carbamazepine, phenobarbital, phenytoin, rifampin may ↓ levels and effectiveness and promote resistance; concurrent use contraindicated.
May ↑ levels and risk of toxicity of lidocaine; monitor lidocaine levels closely.
May ↑ levels and risk of toxicity of digoxin; monitor digoxin levels closely.
May ↑ levels and risk of toxicity of cyclosporine, sirolimus, and tacrolimus; avoid concurrent use with sirolimus; monitor cyclosporine and tacrolimus levels closely.
May ↑ levels and risk of toxicity of abemaciclib, ceritinib, dasatinib, encorafenib, ibrutinib, ivosidenib, neratinib, nilotinib, venetoclax, vinblastine, and vincristine; avoid concurrent use with encorafenib ibrutinib, ivosidenib, neratinib, and venetoclax.
May ↑ or ↓ warfarin levels; closely monitor INR.
May ↑ levels of and risk of bleeding with rivaroxaban; avoid concurrent use.
May ↓ levels and effectiveness of bupropion.
May ↑ levels and risk of toxicity of trazodone; consider ↓ trazodone dose.
May ↑ levels and risk of toxicity of quetiapine; consider ↓ quetiapine dose.
May ↑ levels and risk of toxicity of amlodipine, diltiazem, felodipine, nicardipine, and nifedipine; consider ↓ calcium channel blocker dose.
May ↓ levels and effectiveness of voriconazole; avoid concurrent use.
May ↑ levels and risk of toxicity of atazanavir, bedaquiline, bictegravir, clarithromycin, darunavir, efavirenz, erythromycin, fentanyl, fosamprenavir, isavuconazonium, itraconazole, ketoconazole, maraviroc, midazolam (parenteral) nelfinavir, nevirapine, rifabutin, tenofovir, and tipranavir.
Isavuconazonium, itraconazole, and ketoconazole may ↑ levels and risk of toxicity.
May ↓ levels and effects of raltegravir and zidovudine.
May ↑ levels and risk of toxicity of bosentan; discontinue bosentan ≥36 hr prior to starting nirmatrelvir/ritonavir.
May ↑ levels and risk of toxicity of elbasvir/grazoprevir, glecaprevir/pibrentasvir, ombitasvir/partiaprevir/ritonavir/dasabuvir, and sofosbuvir/velpatasvir/voxilaprevir; avoid concurrent use with glecaprevir/pibrentasvir.
May ↑ levels and risk of toxicity of atorvastatin and rosuvastatin; consider temporarily discontinuing atorvastatin and rosuvastatin during treatment.
May ↓ levels and effectiveness of oral contraceptives containing ethinyl estradiol; use an additional non-hormonal contraceptive during treatment.
May ↑ levels and risk of toxicity of salmeterol; concurrent use not recommended.
May ↓ levels and effectiveness of methadone; monitor patients closely for signs/symptoms of withdrawal.
May ↑ levels and risk of toxicity of betamethasone, budesonide, ciclesonide, dexamethasone, fluticasone, methylprednisolone, mometasone, prednisone, or triamcinolone; consider alternative corticosteroid such as beclomethasone or prednisolone.

Drug-Natural Products:

St. John's wort may ↓ levels and effectiveness and promote resistance; concurrent use contraindicated.

Route/Dosage ⬆ ⬇

PO (Adults ): Two nirmatrelvir 150–mg tablets and one ritonavir 100–mg tablet twice daily for 5 days. Should be started as soon as possible after diagnosis of COVID-19 and within 5 days of symptom onset.

Renal Impairment

PO (Adults ): CCr 30–59 mL/min: One nirmatrelvir 150–mg tablet and one ritonavir 100–mg tablet twice daily for 5 days. Should be started as soon as possible after diagnosis of COVID-19 and within 5 days of symptom onset.

Availability ⬆ ⬇

Tablets: nirmatrelvir 150 mg + ritonavir 100 mg (separate tablets)

Assessment ⬆ ⬇

Assess signs and symptoms of COVID-19 before starting and during therapy.

Implementation ⬆ ⬇

Prior to prescribing Paxlovid: Review all medications taken by the patient to assess potential drug-drug interactions with a strong CYP3A inhibitors and determine if concomitant medications require a dose adjustment, interruption, and/or additional monitoring.
Paxlovid is not approved for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19.
Start 5-day course of Paxlovid as soon as possible after a diagnosis of COVID-19 has been made, and within 5 days of symptom onset even if baseline COVID-19 symptoms are mild. If the patient requires hospitalization due to severe or critical COVID-19 after starting treatment with Paxlovid, patient should complete the full 5-day course.
PO: Administer tablets twice daily without regard to food. Dose packs contain two nirmatrelvir tablets and one ritonavir tablet. Dose for renal impairment contains one nirmatrelvir tablet and one ritonavir tablet. Nirmatrelvir must be co-administered with ritonavir. DNC: Swallow tablets whole; do not break, crush, or chew. Completion of the full 5-day course of therapy and continued isolation in accordance with public health recommendations are important to maximize viral clearance and minimize transmission of SARS-Co-2.

Patient/Family Teaching ⬆ ⬇

Instruct patient to take Paxlovidas directed. If a dose is missed within 8 hr of the time it is usually taken, patient should take it as soon as possible and resume the normal dosing schedule. If the dose is missed by >8 hrs, omit dose and take next dose at regularly scheduled time. Do not double dose to make up for a missed dose. Advise patient to read Patient Information before starting therapy.
Advise patient to notify health care professional if signs and symptoms of hypersensitivity reactions (skin rash, hives or other skin reactions, difficulty in swallowing or breathing, swelling of the lips, tongue, face, tightness of the throat, hoarseness, or other symptoms of an allergic reaction) occur. Advise patient to immediately discontinue Paxlovid and to notify health care professional at the first sign of a reaction.
Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications, especially St. John's wort.
Rep: Advise females of reproductive potential to notify health care professional is pregnancy is planned or suspected or if breastfeeding. Ritonavir may reduce the efficacy of hormonal contraceptives. Advise patients using hormonal contraceptives to use an effective alternative contraceptive method or an additional barrier method of contraception.

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇